SK-MES-1 Cells

SK-MES-1 is a human lung squamous cell carcinoma (LSQCC) cell line extensively used in lung cancer research, particularly in studies focusing on the second most common subtype of non-small cell lung cancer (NSCLC). SK-MES-1 cells are characterized by a high mutation rate in the tumor suppressor gene p53, which is implicated in their resistance to apoptosis and various chemotherapies. This cell line serves as an important model for evaluating novel therapeutic strategies against lung squamous cell carcinoma, particularly for drugs that target the cell cycle and apoptotic pathways.
Studies involving SK-MES-1 have shown that the cell line is responsive to platinum-based chemotherapy agents, such as lobaplatin, which induce apoptosis via both intrinsic and extrinsic pathways. Lobaplatin, a third-generation platinum compound, has been shown to inhibit SK-MES-1 proliferation by inducing S-phase cell cycle arrest and promoting apoptosis through upregulation of pro-apoptotic proteins like Bax and downregulation of anti-apoptotic proteins such as Bcl-2. Additionally, SK-MES-1 cells treated with lobaplatin exhibited an increase in caspase-3, -8, and -9 activation, further supporting the involvement of mitochondrial-mediated apoptosis.
SK-MES-1 has also been used to study the effects of other compounds, such as costunolide, a phytochemical that induces G1/S phase cell cycle arrest and apoptosis via a mitochondria-dependent pathway. Costunolide treatment increases the expression of p53 and Bax, while reducing Bcl-2 levels and disrupting mitochondrial membrane potential, further confirming the utility of SK-MES-1 in studying apoptosis-related pathways in lung squamous carcinoma.